Welcome to our dedicated page for Puretech Health SEC filings (Ticker: PRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PureTech Health plc filings document a foreign private issuer with Nasdaq and LSE-listed securities and a biotherapeutics portfolio organized around wholly owned programs and Founded Entities. Its Form 6-K reports furnish annual results, half-year reports, interim financial reviews, unaudited consolidated financial statements and other material-event disclosures that describe portfolio strategy, cash resources, capital-structure matters and clinical or regulatory updates.
The filing record also covers governance and corporate-management matters, including board changes, leadership transitions and shareholder voting topics. Program-related disclosures identify assets such as deupirfenidone for idiopathic pulmonary fibrosis, LYT-200 for myeloid malignancies, and Seaport Therapeutics neuropsychiatric programs, while formal reports provide the regulatory context for PureTech’s operating model, financial reporting and risk-related disclosures.
PureTech Health plc establishes an American Depositary Receipt program under a Deposit Agreement dated November 11, 2020 with Citibank, N.A. as depositary. Each American Depositary Share (ADS) represents the right to receive ten (10) ordinary shares. The agreement describes issuance, transfer, surrender and withdrawal mechanics, distributions (cash, shares, rights), voting procedures, fees and tax withholding, information and reporting obligations, ownership limits, resignation/removal of the depositary, amendment and termination mechanics, and certain governing law provisions. The company filed a Form 15F and designated https://puretechhealth.com for Rule 12g3-2(b) information publication.
PureTech Health plc submitted a Form 25 notifying the removal of its American Depositary Shares, each representing 10 ordinary shares, from listing and/or registration on The Nasdaq Global Market. The notification is dated May 11, 2026 and is signed by Robert Lyne, Chief Executive Officer.
Citigroup entities filed an amended Schedule 13G/A disclosing collective beneficial ownership of 14,636,273 ordinary shares of PureTech Health plc, representing 6.0% of the class as reported. The filing lists shared voting and dispositive power over the shares and identifies the chain of subsidiaries.
Seaport Therapeutics, Inc. insider entities affiliated with PureTech converted multiple series of preferred stock into Common Stock in connection with the company’s initial public offering. The Form 4 shows automatic conversions of Series A-1, Series A-2 and Series B Preferred Stock into Common Stock on a stated one-for-3.1407 basis.
PureTech LYT, Inc. is the record holder of all reported securities, with PureTech Health LLC and PureTech Health plc controlling voting and disposition power through their ownership chain. The transactions are coded as conversions of derivative securities, increasing indirect Common Stock holdings rather than reflecting open-market buying or selling.
PureTech Health plc reports that its founded entity, Seaport Therapeutics, has priced an upsized initial public offering of 14,160,000 shares of common stock at $18.00 per share, at the top of the target range, for expected gross proceeds of $254.9 million before fees and expenses. Underwriters have a 30-day option to buy an additional 2,124,000 shares at the IPO price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the symbol “SPTX,” with closing expected on May 4, 2026 subject to customary conditions. After the offering closes, PureTech expects to hold 16,685,013 Seaport common shares.
PureTech Health plc, through its subsidiary PureTech LYT, Inc., has filed an initial ownership report for Seaport Therapeutics, Inc. (SPTX). The filing shows indirect holdings of 302,479 shares of common stock and several series of preferred stock.
PureTech LYT, Inc. is the record holder of all reported securities, while PureTech Health plc ultimately controls voting and disposition through an intermediate LLC. The Series A-1, A-2 and B preferred shares are convertible into common stock at the holder’s election and will automatically convert into common stock upon the closing of Seaport’s initial public offering, for no additional consideration.
PureTech Health plc ownership disclosure: Tang Capital Management, LLC and affiliated filers report beneficial ownership of 12,635,782 Ordinary Shares, equal to 5.19% of the class. The statement cites 243,418,190 Ordinary Shares outstanding as of March 31, 2026 from the Month End Disclosure of Total Voting Rights and Share Capital filed with the London Stock Exchange on April 1, 2026.
The filing states the holders have shared voting and shared dispositive power over the reported shares, with the positions held jointly by Tang Capital entities and Kevin Tang.
PureTech Health plc ownership disclosure: Tang Capital Management, LLC and affiliated filers report beneficial ownership of 12,635,782 Ordinary Shares, equal to 5.19% of the class. The statement cites 243,418,190 Ordinary Shares outstanding as of March 31, 2026 from the Month End Disclosure of Total Voting Rights and Share Capital filed with the London Stock Exchange on April 1, 2026.
The filing states the holders have shared voting and shared dispositive power over the reported shares, with the positions held jointly by Tang Capital entities and Kevin Tang.
PureTech Health plc, a biotechnology company incorporated in England and Wales, has filed its annual report on Form 20-F for the year ended December 31, 2025. Its American Depositary Shares (each representing 10 ordinary shares) trade on the Nasdaq Global Market under the symbol PRTC.
The company focuses on therapeutic candidates within its Wholly-Owned Programs and a group of Founded Entities. As of December 31, 2025, it had never generated revenue from therapeutic candidates within its Wholly-Owned Programs and highlights that it may never be operationally profitable, emphasizing ongoing dependence on substantial additional funding.
The filing summarizes extensive risk factors typical for clinical-stage biotech, including clinical and regulatory uncertainty, potential safety issues, manufacturing challenges, intellectual property protection, reliance on third parties and collaborators, and significant volatility in the market price of its ADSs.
PureTech Health plc, a biotechnology company incorporated in England and Wales, has filed its annual report on Form 20-F for the year ended December 31, 2025. Its American Depositary Shares (each representing 10 ordinary shares) trade on the Nasdaq Global Market under the symbol PRTC.
The company focuses on therapeutic candidates within its Wholly-Owned Programs and a group of Founded Entities. As of December 31, 2025, it had never generated revenue from therapeutic candidates within its Wholly-Owned Programs and highlights that it may never be operationally profitable, emphasizing ongoing dependence on substantial additional funding.
The filing summarizes extensive risk factors typical for clinical-stage biotech, including clinical and regulatory uncertainty, potential safety issues, manufacturing challenges, intellectual property protection, reliance on third parties and collaborators, and significant volatility in the market price of its ADSs.
PureTech Health released its annual results for the year ended December 31, 2025 and outlined a more focused, capital‑efficient strategy built around its hub‑and‑spoke model. PureTech level cash, cash equivalents and short‑term investments were $277.1 million as of December 31, 2025, and management expects an operational runway at least through the end of 2028, including planned participation in Founded Entity financings.
The portfolio is led by Celea Therapeutics’ Phase 3‑ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s LYT‑200 for relapsed/refractory high‑risk myelodysplastic syndrome and acute myeloid leukemia, and Seaport Therapeutics’ clinical‑stage neuropsychiatric pipeline, which is pursuing an IPO via a filed Form S‑1. PureTech reported 2025 revenue of $4.7 million, largely from contract and royalty revenue, with general and administrative expenses of $46.6 million and research and development expenses of $56.6 million, resulting in a net loss attributable to owners of $109.7 million.
The company plans to house major programs in externally funded Founded Entities to lower central operating costs and reduce risk concentration, and it expects a significant reduction in operational burn after Celea’s planned financing closes. PureTech also intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange, aiming for a simpler structure and lower administrative cost while maintaining access to global investors.
PureTech Health released its annual results for the year ended December 31, 2025 and outlined a more focused, capital‑efficient strategy built around its hub‑and‑spoke model. PureTech level cash, cash equivalents and short‑term investments were $277.1 million as of December 31, 2025, and management expects an operational runway at least through the end of 2028, including planned participation in Founded Entity financings.
The portfolio is led by Celea Therapeutics’ Phase 3‑ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s LYT‑200 for relapsed/refractory high‑risk myelodysplastic syndrome and acute myeloid leukemia, and Seaport Therapeutics’ clinical‑stage neuropsychiatric pipeline, which is pursuing an IPO via a filed Form S‑1. PureTech reported 2025 revenue of $4.7 million, largely from contract and royalty revenue, with general and administrative expenses of $46.6 million and research and development expenses of $56.6 million, resulting in a net loss attributable to owners of $109.7 million.
The company plans to house major programs in externally funded Founded Entities to lower central operating costs and reduce risk concentration, and it expects a significant reduction in operational burn after Celea’s planned financing closes. PureTech also intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange, aiming for a simpler structure and lower administrative cost while maintaining access to global investors.
PureTech Health plc plans to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading of its equity on the London Stock Exchange, which will remain its primary listing venue. Each ADS represents the right to receive ten ordinary shares.
The company expects to file Form 25 on or about May 11, 2026, with delisting becoming effective ten days later and the last trading day for ADSs on Nasdaq expected on or about May 20, 2026. After delisting, PureTech anticipates its ADSs will trade over-the-counter via a sponsored Level 1 ADR program, with no immediate action required from ADS holders.
PureTech also intends to file Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, with termination expected to become effective no later than 90 days after that filing, absent SEC objection.
PureTech Health plc plans to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading of its equity on the London Stock Exchange, which will remain its primary listing venue. Each ADS represents the right to receive ten ordinary shares.
The company expects to file Form 25 on or about May 11, 2026, with delisting becoming effective ten days later and the last trading day for ADSs on Nasdaq expected on or about May 20, 2026. After delisting, PureTech anticipates its ADSs will trade over-the-counter via a sponsored Level 1 ADR program, with no immediate action required from ADS holders.
PureTech also intends to file Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, with termination expected to become effective no later than 90 days after that filing, absent SEC objection.